ArrowMark Partners
100 Fillmore Street, Suite 325, Denver, CO, 80206, United States
Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Poplar Therapeutics | Mar 2026Participated | $45 MSeries A | |
Skyryse | Feb 2026Participated | $300 MSeries C | |
Frontier Medicines | Jun 2024Participated | $20 MSeries C | |
Zenas BioPharma | May 2024Participated | $200 MSeries C | |
Freenome | Feb 2024Participated | $254 MOther Equity | |
SmartLabs | Jan 2024Participated | $48 MSeries C | |
Beta Bionics | Sep 2023Participated | $100 MSeries D | |
Checkerspot | Feb 2023Led | $55 MSeries C | |
Aktis Oncology | Aug 2022Led | $84 MSeries A | |
Dren Bio | Jun 2022Participated | $65 MSeries B | |
Beta Bionics | Feb 2022Participated | $57 MSeries C | |
Simcha Therapeutics | Jan 2022Participated | $40 MSeries B | |
Poplar Therapeutics | Mar 2026Participated | $45 MSeries A | |
Skyryse | Feb 2026Participated | $300 MSeries C | |
Frontier Medicines | Jun 2024Participated | $20 MSeries C | |
Zenas BioPharma | May 2024Participated | $200 MSeries C | |
Freenome | Feb 2024Participated | $254 MOther Equity | |
SmartLabs | Jan 2024Participated | $48 MSeries C | |
Beta Bionics | Sep 2023Participated | $100 MSeries D | |
Checkerspot | Feb 2023Led | $55 MSeries C | |
Aktis Oncology | Aug 2022Led | $84 MSeries A | |
Dren Bio | Jun 2022Participated | $65 MSeries B | |
Beta Bionics | Feb 2022Participated | $57 MSeries C | |
Simcha Therapeutics | Jan 2022Participated | $40 MSeries B |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 1 | 1 |
| Series B | 3 | 16 |
| Series C+ | 2 | 22 |
| Other Equity | 0 | 6 |
| Debt | 0 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| May '17 | 1 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 0 |
| Oct '17 | 0 |
| Nov '17 | 1 |
| Dec '17 | 1 |
| Jan '18 | 1 |
| Feb '18 | 1 |
| Mar '18 | 1 |
| Apr '18 | 1 |
| May '18 | 0 |
| Jun '18 | 2 |
| Jul '18 | 2 |
| Aug '18 | 2 |
| Sep '18 | 2 |
| Oct '18 | 0 |
| Nov '18 | 1 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 1 |
| May '19 | 1 |
| Jun '19 | 0 |
| Jul '19 | 1 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 1 |
| Jan '20 | 2 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 1 |
| Jul '20 | 0 |
| Aug '20 | 1 |
| Sep '20 | 1 |
| Oct '20 | 0 |
| Nov '20 | 1 |
| Dec '20 | 1 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 1 |
| Apr '21 | 1 |
| May '21 | 1 |
| Jun '21 | 1 |
| Jul '21 | 1 |
| Aug '21 | 1 |
| Sep '21 | 2 |
| Oct '21 | 1 |
| Nov '21 | 2 |
| Dec '21 | 1 |
| Jan '22 | 2 |
| Feb '22 | 1 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 1 |
| Jul '22 | 0 |
| Aug '22 | 1 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 1 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 1 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 1 |
| Feb '24 | 1 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 1 |
| Jun '24 | 1 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 1 |
| Mar '26 | 1 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 45 |
| Networks, Cloud & Communication | 6 |
| Space & Frontier Tech | 5 |
| Travel & Hospitality | 3 |
| Media & Entertainment | 3 |
| Professional Services | 3 |
| Real Estate & Construction | 3 |
| Transportation & Logistics | 2 |
| Marketing & Advertising | 1 |
| Manufacturing | 1 |
| AI & Machine Learning | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 1 |
| $25M-$50M | 9 |
| $50M-$100M | 20 |
| $100M-$250M | 15 |
| $250M-$500M | 6 |
| $500M-$1B | 1 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 50 |
| China | 1 |
| Europe | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Perceptive Advisors | 16 |
| RA Capital Management | 10 |
| Fidelity Management & Research Company | 8 |
| Alexandria Venture Investments | 7 |
| Casdin Capital | 7 |
| Janus Henderson Investors | 7 |
| Polaris Partners | 7 |
| Soleus Capital | 7 |
| Redmile Group | 6 |
| BVF Partners | 5 |
| Eventide Asset Management | 5 |
| OrbiMed | 5 |
| RTW Investments | 5 |
| Sands Capital | 5 |
| T. Rowe Price Associates | 5 |
| Venrock | 5 |
| Deep Track Capital | 4 |
| Driehaus Capital Management | 4 |
| Farallon Capital Management | 4 |
| Franklin Templeton | 4 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 6 | 12% |
| Participating | 46 | 88% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 4 | 67% |
| Co-led | 2 | 33% |
Team
Co-Founding Partner & Portfolio Manager
Co-Founding Partner & Portfolio Manager
Managing Director and Investment Committee Member
Portfolio Manager
Managing Director and Investment Committee Member